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FBW7 (F-box and WD repeat domain-containing 7) has been characterized as an onco-suppressor
protein in human cancers. Recent studies have also shown that FBW7 exerts its anti-tumor function
primarily by promoting the degradation of various oncoproteins, through which FBW7 regulates
cellular proliferation, differentiation and causes genetic instability. In this review, we will discuss
the role of FBW7 downstream substrates and how dysregulation of Fbw7-mediated proteolysis of
these substrates contributes to tumorigenesis. Additionally, we will also summarize the currently
available various Fbw7-knockout mouse models that support Fbw7 as a tumor suppressor gene in
the development and progression of human malignancies.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The abundance of many cellular proteins, which are involved in
diverse cellular processes including cell cycle progression, cell pro-
liferation, and cell apoptosis, is governed by the ubiquitin protea-
some system (UPS) through ubiquitination-mediated degradation
by the 26S proteasome [1]. Due to mutated components of the
UPS, elevated degradation of certain tumor suppressor proteins
or impaired destruction of oncoproteins appears to lead to tumor
development [1]. It is well documented that the UPS is rather com-
plex and consists of the ubiquitin-activating enzyme (E1), the
ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligases
(E3). The E1 utilizes ATP to activate ubiquitin for conjugation and
transfers it to E2. The E2 enzyme interacts with a speciﬁc E3 part-
ner and transfers the ubiquitin to the target protein, guiding the
substrate for degradation [1]. It is worth mentioning that the spec-
iﬁcity of target protein selection is mainly dependent on the indi-
vidual E3 enzyme. In this regard, there are hundreds of different E3
enzyme identiﬁed in human, which theoretically provides thechemical Societies. Published by E
thology, Beth Israel Deacon-
ookline Avenue, Boston, MA
ei).necessary speciﬁcity for the extending list of targets to be degraded
by the UPS [1].
Among the E3 enzymes, the SCF (SKP1-CUL1-F-box protein) E3
ligase complex, which consists of Skp1 (S-phase kinase-associated
protein 1), Cul1, Rbx1/Roc1, and a variable subunit denoted as the
F-box protein, has been well characterized [2]. Importantly, the
F-box protein determines target speciﬁcity through recognition
and binding of target proteins for ubiquitination and degradation.
So far, more than 70 putative F-box proteins have been identiﬁed
in human genome, although the function and their substrates of
most F-box proteins remain elusive [3]. One well-studied F-box-
containing protein is FBW7 (F-box and WD repeat domain-con-
taining 7) also known as FBXW7. The ﬁrst member of the FBW7
gene family was originally identiﬁed in budding yeast and called
Cdc4 [4]. It is known that human FBW7 is located on chromosome
4 and encodes three transcripts (isoforms a, b and c) derived from
the same gene locus by alternative splicing. All three isoforms vary
at the N-terminal region but contain conserved interaction do-
mains in the C-terminus (F-box and WD40 repeats). Three FBW7
a, b and c isoforms localize to the nucleoplasm, cytoplasm and
nucleolus, respectively [3]. The F-box motif is a 40 amino acid re-
gion within each F-box protein that recruits the SCF complex by di-
rectly interacting with Skp1 to form a functional E3 ligase complex
[3]. Also present at the C-terminal region of FBW7 is a stretch oflsevier B.V. All rights reserved.
Fig. 1. Schematic illustration of a SCF-type of E3 ubiquitin ligase complex. The SCF
(Skp1-Cullin 1-F-box) complex consists of four components: the invariable com-
ponent Skp1, Rbx1 and Cullin1, and the interchangeable F-box protein that
functions as a receptor for target proteins. FBW7 recognizes the targeted substrates,
which are presented closely to the E2 enzyme to ensure consequent conjugation of
ubiquitin. The addition of polyubiquitin targets proteins to the 26S proteasome for
degradation.
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Recently, FBW7 is believed to serve as a tumor suppressor through
negative regulation of many oncogenic proteins [3]. Therefore, in
the following section, we will discuss what substrate has been
identiﬁed thus far as the major FBW7 substrates as well as discuss
the roles of its upstream regulatory factors, highlighting the novel
functions of FBW7 in carcinogenesis.
2. The downstream substrates of FBW7
Recent studies have identiﬁed multiple speciﬁc substrates
of FBW7 including Cyclin E [5], c-Myc [6,7], c-Jun [8,9], Notch
[10,11], Mcl-1 (Myeloid cell leukemia-1) [12,13], SREBP (Sterol reg-
ulatory element-binding proteins) [14,15], mTOR (mammalian tar-
get of rapamycin) [16], KLF5 (Kruppel-like factor 5) [17,18], c-Myb
[19–21], Aurora A [22], NF1 (Neuroﬁbromatosis type 1) [23], NRF1
(Nuclear factor E2-related factor 1) [24], and HIF-1a (Hypoxia
inducible factor-1a) [25,26]. More recently, Busino and colleague
identiﬁed that p100 is a new FBW7 substrate [27]. FBW7a targets
nuclear p100 for proteasomal degradation on phosphorylation of
p100 by GSK3 (glycogen synthase kinase 3) [27]. Here, we will
brieﬂy discuss several key substrates that would help us to under-
stand the critical role of FBW7 in cell cycle progression, apoptosis,
tumor metastasis, and drug resistance.
2.1. Myeloid cell leukemia-1
Mcl-1, a pro-survival member of the Bcl-2 family, is frequently
elevated in various human tumors, suggesting that Mcl-1 is an
attractive and potential therapeutic target for human malignancies
[28]. Targeted inactivation of Mcl-1 has been shown to therapeuti-
cally important [28]. It has been identiﬁed that two E3 ubiquitin
ligases, namely MULE (Mcl-1 ubiquitin ligase E3) and b-TRCP
(beta-transducin repeat containing protein), polyubiquitinate and
target Mcl-1 for degradation [29,30]. Conversely, deubiquitinase
USP9X (Ubiquitin speciﬁc peptidase 9 X-linked) stabilizes Mcl-1
through reversing its polyubiquitination [31]. Recently, we and
others have identiﬁed that FBW7 regulates cellular apoptosis by
controlling the ubiquitination and destruction of the Mcl-1 in a
GSK3 phosphorylation-dependent manner [12,13].
In the following paragraph, we will discuss the regulation of
Mcl-1 by FBW7 in more detail than other substrates, which serves
as an example for initiating cutting-edge research for better under-
standing of how FBW7, an E3 ligase, could execute its anti-tumor
functions mediated via promoting the degradation of its sub-
strates. First, FBW7 substrates typically contain the conservedCPD (Cdc4 phospho-degron) sequence (L)-X-pT/pS-P-(P)-X-pS/pT/
E/D (X = any amino acid) [12]. Second, proper phosphorylation of
the substrate is required for FBW7 to recognize and target its sub-
strate for ubiquitylation. Indeed, we identiﬁed the putative FBW7
phosphodegron sequence in Mcl-1, which is conserved across dif-
ferent species [12]. Moreover, we identiﬁed S159 and T163 within
the phosphodegron as the major GSK3-mediated phosphorylation
sites as well as S121 as a minor GSK3-mediated phosphorylation
site. Not surprisingly, inactivation of these GSK3-mediated phos-
phorylation sites impairs the interaction between Mcl-1 and
FBW7 [12]. To further support this result, pharmacological inhibi-
tion of GSK3 activity blocked the interaction between FBW7 and
Mcl-1, suggesting that GSK3-dependent phosphorylation of Mcl-1
is required for the interaction of Mcl-1 with FBW7 [12]. Another
group led by Dr. Dixit and Dr. Wertz also reported similar results
[13]. They identiﬁed similar Mcl-1 degron motifs and protein ki-
nases that direct recruitment to FBW7 during mitotic arrest [13].
Furthermore, they discovered S64, S121, S159 and T163 sites in
Mcl-1 as GSK3-mediated phosphorylation sites [13]. Taken to-
gether, results from both groups consistently showed that FBW7-
mediated degradation of Mcl-1 was dependent on GSK3-mediated
Mcl-1 phosphorylation at multiple Ser/Thr sites within the phos-
phodegron sequence. More importantly, these two independent
groups have shown that FBW7 plays important roles in the regula-
tion of drug sensitivity via governing Mcl-1 degradation.
2.2. Hypoxia inducible factor-1a
HIF-1a is a major transcription factor involved in cellular re-
sponse to hypoxia (low oxygen) [32]. Hypoxia is a common feature
of human malignancies that contributes to progression of cancer
such as tumor metastasis [33]. HIF-1a has been found to stimulate
the expression of genes associated with angiogenesis including
VEGF (vascular endothelial growth factor) and Glut1 [33]. Overex-
pression of HIF-1a has been identiﬁed in various types of human
cancers including prostate, breast, and ovarian cancer [34].
Moreover, a number of studies from various laboratories have
demonstrated that increased levels of HIF-1a correlate with poor
prognosis such as reduced patient survival in many types of human
cancers [32,34]. Therefore, it is critical to understand the molecular
mechanisms governing the functional role of HIF1a overexpression
and the regulation of its degradation.
HIF-1a protein is tightly regulated by post-translational modiﬁ-
cation such as phosphorylation, nitrosylation, and sumoylation,
leading to its proper expression levels [33,34]. Dysregulation of
HIF-1a could contribute to angiogenesis, which is a process known
to promote tumor growth and metastasis [32]. Although earlier
studies have clearly demonstrated that the VHL (von Hippel-Lin-
dau) tumor suppressor, which is frequently mutated/deleted in
the kidney tumors, is the major E3 ligase governing HIF1a stability
[35,36], it remains largely unknown how HIF1a destruction is
deregulated in other types of human tumors. Recently, two sepa-
rated groups have identiﬁed HIF-1a as new FBW7 substrate
[25,26]. Under normoxia, HIF-1a is ubiquitinated and degraded
by VHL [37] whereas under hypoxia, HIF-1a is targeted for ubiqui-
tin-dependent degradation through FBW7 interactions and subse-
quent phosphorylation by GSK3b [25]. Moreover, GSK3b and
FBW7-dependent HIF-1a degradation can be antagonized by the
USP28 (ubiquitin speciﬁc peptidase-28), suggesting that FBW7
and USP28 could reciprocally regulate cell migration and angiogen-
esis in a HIF-1adependent manner [26].
2.3. Kruppel-like factor 5
KLF5 transcription factor has been shown to play important
roles in tumorigenesis [38], but its exact function remains
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cer, and it serves as a prognostic factor for disease-free survival and
overall survival in patients diagnosed with breast cancer [39].
Moreover, KLF5 was reported to promote cell proliferation and
tumorigenesis in a variety of human cancers such as breast cancer
and bladder cancer [40–42]. Furthermore, inhibition of KLF5 signif-
icantly suppressed tumor growth in vivo, suggesting that KLF5 may
function as an oncogenic transcription factor, thereby it is a poten-
tial therapeutic target for the treatment of human cancers [40,41].
However, several studies have demonstrated frequent loss of func-
tion of KLF5 by deletion and/or because of its loss of expression in
breast cancer, AML (acute myeloid leukemia), and prostate cancer,
arguing that in certain cellular contexts, KLF5 might be a possible
tumor suppressor [43–45]. Therefore further investigation is
needed to delineate the exact role of KLF5 in human tumorigenesis.
Recently, Zhao et al. found that FBW7 targets KLF5 for ubiqui-
tin-mediated proteasomal degradation [18]. Initially, this group
observed that KLF5 contains two putative evolution-conserved
CPD motifs that could recruit FBW7 [18]. Next, the authors showed
that the GSK3b kinase is involved in the phosphorylation of KLF5 at
the S303 site, which is required for FBW7 to target KLF5 for ubiq-
uitination and degradation [18]. Additionally, overexpression of
FBW7 decreases the KLF5 protein level and its half-life, while inac-
tivation of FBW7 increases the KLF5 protein and half-life [18].
More importantly, FBW7 inhibits breast cancer cell proliferation,
at least, partly due to promotion of KLF5 proteolysis. Consistent
with this ﬁnding, Liu et al. also found that FBW7 speciﬁcally pro-
moted the degradation and ubiquitination of KLF5 in a GSK3b-
phosphorylation-dependent manner [17]. Taken together, studies
from these two groups support the notion that FBW7 is a key neg-
ative regulator controlling KLF5-mediated cell proliferation.
2.4. Nuclear factor E2-related factor 1
NRF1 belongs to the CNC (cap-n-collar) subfamily of basic-leu-
cine zipper transcription factors [46]. It has been reported that
NRF1 can direct ARE (antioxidant response element)-mediated
expression of target genes, which respond to oxidative stress
[47]. Speciﬁcally, NRF1 regulates the genes encoding enzymes in-
volved in glutathione biosynthesis and other oxidative defense en-
zymes [47]. NRF1 can induce the expression of MT-1 and MT-2
(metallothionein-1 and -2), protecting cells from heavy metal-in-
duced damage [48]. Aside from response to oxidative stress,
NRF1 has also been found to play a pivotal role in controlling var-
ious other cellular processes [47]. For example, it has been demon-
strated that NRF1 interacts with C/EBP-b (CCAAT enhancer-binding
protein beta) to negatively regulate the odontoblast differentiation
[49]. Unfortunately, although multiple groups have tried to inves-
tigate the biological roles of NRF1, physiological functions of NRF1
remain largely elusive. It has been reported that the loss of NRF1
function in mice leads to anemia and embryonic lethality, suggest-
ing that NRF1 as an essential gene during development [50]. More-
over, liver-speciﬁc inactivation of the NRF1 gene in adult mouse
leads to steatohepatitis and hepatic neoplasia, indicating that
NRF1 possibly functions as a tumor suppressor [51]. However,
the molecular mechanism underlying NRF1’s anti-tumor activity
requires further investigations.
Recently, it was found that FBW7 regulates the turnover of
NRF1 transcription factor through proteasome-mediated proteoly-
sis [24]. The group led by Dr. Chan provides further evidence to
support this notion. First, NRF1 is an unstable protein since it has
shorter half-life. Second, using MG132 treatment and in vivo ubiq-
uitination assay, they showed that NRF1 is degraded by ubiquitin-
dependent pathway. Third, NRF1 and FBW7a interact with each
other. Fourth, knockdown of FBW7 by shRNA stabilizes NRF1. Fifth,
FBW7 regulates NRF1 via a CPD motif at residues 350–354. Sixth,activation of NRF1-dependent transcription is governed by FBW7
expression [24]. Taken together, NRF1 is an ubiquitin substrate of
FBW7. Since both FBW7 and NRF1 are tumor suppressor proteins,
therefore it is difﬁcult to appreciate the signiﬁcance of FBW7-med-
iated NRF1 destruction in tumorigenesis. In this regard, the author
argued that increased NFR1 due to FBW7 deﬁciency might promote
cells to undergo cellular transformation, thus providing a growth
advantage mediated by up-regulation of stress response genes
[24]. It is also possible that up-regulation of NRF1, together with
c-Myc, c-Jun, and Cyclin E, which are known FBW7 substrates, pro-
mote tumorigenesis [24]; however, further studies are warranted
before reaching a solid conclusion.
2.5. Neuroﬁbromatosis type 1
NF1 is a tumor suppressor gene that is frequently mutated in a
variety of human cancers, including lung cancer, glioblastomamul-
tiforme, neuroﬁbrosarcomas, and pheochromocytomas [52–54]. In
mouse models, the homozygous NF1/ embryos die between E
11.0 and E 13.5 days with many defects such as retarded eye devel-
opment and malformation of the heart outﬂow vessels [55]. NF1+/
mice are also predisposed to the formation of phaeochomocytoma
and myeloid leukemia [56]. Moreover, loss of NF1 function has
been found in human malignancies. Since NF1 accelerates the con-
version of activated GTP-bound Ras to inactive GDP-Ras, thus the
loss of NF1 exhibits elevated GTP-bound Ras (the active form of
Ras) thereby promoting tumorigenesis [53]. Therefore, NF1 is a
well-characterized tumor suppressor gene.
Recently, multiple studies have demonstrated that NF1 stability
is governed by the ubiquitin–proteasome pathway [57–59].
Cichowski et al. found that NF1 is degraded through ubiquitin-
mediated proteolysis by 26S proteasome in response to serum
and growth factors such as EGF (epithelial growth factor), PDGF
(platelet derived growth factor) and LPA (lysophosphatidic acid)
[57]. Moreover, sequences adjacent to the NF1 GRD (GAP-related
domain) are required for NF1 degradation [57], suggesting that
the dynamic proteasomal regulation of NF1 controls Ras-mediated
signaling pathway. This group recently demonstrated that NF1 is
inactivated in sporadic gliomas in part through excessive proteaso-
mal degradation of NF1 [58]. Speciﬁcally, NF1 is destabilized by
PKC (protein kinase C) and the proteasome, leading to the activa-
tion of Ras and tumorigenesis [58]. In addition, Phan et al. showed
that ETEA, which contains both UBA and UBX domains, ubiquiti-
nates NF1 [59]. More importantly, a recent study led by Dr. Sun
discovered that NF1 is a physiological substrate of the SAG (sensi-
tive to apoptosis gene)-Cul1-FBW7 E3 ubiquitin ligase [23]. NF1
contains an FBW7-binding motif at the C terminus, which is neces-
sary for its ubiquitination. Furthermore, SAG-Cul1-FBW7 binds to
NF1 as a complex and promotes NF1 ubiquitination. As a result
of FBW7-mediated ubiquitination of NF1, FBW7 and SAG signiﬁ-
cantly shorten NF1 protein half-life. Moreover, FBW7 and SAG
are required for degradation of NF1 upon mitogen stimulation
[23]. Therefore, this study provides an FBW7-dependent regulatory
mechanism for the NF1-Ras pathway.
2.6. Cyclin E
Cyclin E is a critical regulator of the cell cycle progression that is
frequently upregulated in cancer [60]. The function of Cyclin E is to
bind and activate the CDK2 (cyclin-dependent kinase 2), leading to
phosphorylation of various downstream substrates involved in cell
cycle progression [60]. It has been discovered that the amount of
Cyclin E protein is tightly controlled and destructed by FBW7 [5].
FBW7 can associate speciﬁcally with phosphorylated Cyclin E
and catalyze its ubiquitination [5]. Cyclin E has been considered
as a key mediator for the ability of FBW7 to inhibit tumorigenisis.
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abrogated genomic instability that caused by loss of FBW7 in
HCT116 colon cancer cells [61]. In support this notion, Minella
et al. demonstrated that mutant Cyclin E, which cannot be de-
graded by FBW7, whereas deletion of FBW7 can be achieved by
inducing genomic instability [62]. Furthermore, transgenic mice
expressing the non-degradable version of Cyclin E mutant display
increased susceptibility to Ras-induced lung cancer due to elevated
genetic instability [63]. However, in-depth investigation is needed
to elucidate the exact molecular mechanism underlying the anti-
tumor activity of FBW7 that is mediated through degradation of
Cyclin E.
2.7. Notch
Most studies have shown oncogenic functions of Notch in many
human carcinomas with up-regulation of Notch expression [64]. It
is known that Notch signaling pathway plays pivotal roles in many
key cellular processes such as cell proliferation, differentiation and
apoptosis, thus deregulation of Notch may contribute to carcino-
genesis [65]. Thus far, four Notch receptors (Notch 1–4) and ﬁve li-
gands (Dll-1, 3, 4, Jagged-1, 2) have been identiﬁed in mammals.
Notch signaling is activated after ligand binding to an adjacent
Notch receptor, subsequently leading to a series of proteolytic
cleavages by the metalloprotease, tumor necrosis factor-a-con-
verting enzyme and the c-secretase complex (presenilin, nicastrin,
Pen-2, and Aph-1) [64]. Oberg et al. ﬁrstly identiﬁed that Notch is
ubiquitinated and negatively regulated by FBW7 through a genetic
screen [66]. In support of this ﬁnding, mice lacking the FBW7
exhibited elevated Notch expression and subsequently impaired
cardiovascular development [10]. Moreover, FBW7 mutations in
leukemic cells were found to result in Notch pathway activation
through inhibition of Notch degradation [67]. Recently, it has been
demonstrated that SGK1 (serum- and glucocorticoid-inducible
protein kinase 1) signiﬁcantly reduced the Notch-1 stability
through FBW7 [68]. Moreover, the intracellular domain of Jag-
ged-1 was also found to interact with Notch1 intracellular domain
and promote its degradation through FBW7-dependent proteaso-
mal pathway [69]. Interestingly, presenilin, one of the components
of the c-secretase complex was found to regulate the ubiquitin li-
gase FBW7 to modulate EGFR signaling and cell transformation
[70]. These and other ﬁndings suggest the importance of FBW7
in the regulation of Notch signaling, and as such calls for further
in-depth research.
2.8. Other substrates
In addition to these substrates as we have discussed above,
some oncoproteins have also been identiﬁed as FBW7 substrates
including c-Jun [8,9], c-Myc [6,7], mTOR [16], c-Myb [19,20], and
Aurora A [22]. It has been shown previously that c-Jun, induced
by many mitogens, has positive effects on cell proliferation. We
have discovered that FBW7 regulates the degradation of c-Jun in
a GSK3 phosphorylation-dependent manner [9]. Moreover, the
point mutation in the v-Jun protein allows v-Jun to escape GSK3-
dependent recognition and destruction by the FBW7 [9]. Similar
to c-Jun, c-Myc is an oncoprotein that was found routinely acti-
vated in approximately 70% of all human cancers. Several studies
have coherently shown that FBW7 regulates GSK3 phosphoryla-
tion-dependent c-Myc protein degradation [6,7]. Interestingly,
later studies showed that FBW7-mediated degradation of c-Myc
can partially be counteracted by the USP28 [71].
Furthermore, the mTOR protein has emerged as an oncoprotein
for controlling many cellular processes, such as cell growth and cell
division. Interestingly, the mTOR protein was also found to be de-
graded through the GSK3/FBW7-dependent mechanism [16,72].Moreover, tumor cell lines harboring inactivation of FBW7 are par-
ticularly sensitive to mTOR inhibitor rapamycin treatment, indicat-
ing that loss of FBW7 could be a biomarker of human cancer
susceptibility to mTOR inhibitor treatment [72]. Additionally,
c-Myb, a transcription factor with elevated expression in many
human cancers, was found to be ubiquitinated and degraded by
FBW7 in a NIK/GSK3-dependent manner [19,21]. Thus, it is clear
that most of these oncoproteins are identiﬁed as FBW7 substrates,
suggesting that FBW7 mediated degradation of oncoproteins may
serve as anti-tumor mechanism in human cancers.3. FBW7 knockout mouse models
To better understand the underlying mechanisms of develop-
ment and tumor formation due to deregulated FBW7, several
FBW7 knockout mouse models have been developed using gene
knockout strategies in ES (embryonic stem) cells. In the following
paragraphs, we will focus our discussion on these mouse models
to understand the anti-cancer function of FBW7.
3.1. FBW7/ mice
Several groups including Dr. Nakayama’s laboratory have gener-
ated mice deﬁcient in FBW7 [10,11]. Accumulated evidence has
shown that FBW7/ embryos die in utero at embryonic day 10.5
[11]. Speciﬁcally, it has growth retardation, especially in the head
region in all homozygous mutant embryos [11]. Moreover, im-
paired vascular development was found in the FBW7/ mice. For-
mation of the major veins such as the anterior cardinal vein was
severely impaired in FBW7/ embryos [11]. Furthermore, accu-
mulation of Notch-4 and enhanced expression of Hey-1 were found
in FBW7/ mice, suggesting that Notch-4 and its downstream
gene Hey-1 could play an important role in the repression of ve-
nous cell fate determination as well as determination of vascular
network formation [11]. Consistent with this notion, the group
led by Dr. Elledge demonstrated similar results where they found
that FBW7/ mice have defective cardiovascular development
and elevated Notch proteins [10]. Further studies revealed that
FBW7/ mice die due to a combination of deﬁciencies in vascular
and hematopoietic, and atrial as well as ventricular chamber for-
mation development [10]. Abnormalities in cardiovascular devel-
opment in FBW7/ mice are due to the results of dysregulation
of Notch-1 and Notch-4 [10]. Interestingly, these two independent
groups showed different expression levels of Cyclin E in FBW7/
mice, suggesting that FBW7-mediated destruction of substrates
may vary in different cellular contexts. Obviously, further investi-
gation is required to determine the exact functions of Cyclin E in
FBW7 knockout mice.
3.2. Conditional FBW7/ mice
To better understand the physiological functions of FBW7 in
tumorigenesis, speciﬁcally because of the limitation of embryonic
mortality associated with the FBW7/ mice, the conditional abla-
tion of FBW7 in various adult tissues with tissue-speciﬁc expres-
sion of Cre could be a practical strategy. So far, conditional
inactivation of FBW7 in the T-cell lineage, bone marrow, intestine,
liver, breast and brain has been reported [73–80]. In the following
sections, we will brieﬂy discuss these conditional FBW7/ mouse
models, which coherently support a pivotal role for FBW7 in sup-
pressing tumorigenesis in vivo.
3.2.1. FBW7/ in T-cell lineage
It has been shown that mice with conditional inactivation of
FBW7 in the T-cell lineage are predisposed to thymic lymphoma
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have massive thymic enlargement. Moreover, thymus in these
mice contains a uniform population of immature lymphoid cells
with necrosis [78]. Both CD4 and CD8 are expressed on thymic
lymphoma cells, suggesting an accumulation of immature T cells
in the lymphomas [78]. Furthermore, loss of FBW7 in T cells
develops thymic lymphoma in part due to excessive accumulation
of c-Myc [78]. More importantly, the double mutant mice that have
knockout FBW7 in T cells combination with ablation of p53
develop thymic lymphomas at a markedly increased frequency
and with a reduced latency [78], indicating a potential synergistic
interaction between loss of FBW7 and p53 tumor suppressors in
facilitating tumorigenesis.
3.2.2. FBW7/ in bone marrow
To investigate the role of FBW7 in hematopoietic cells, the bone
marrow (BM)-speciﬁc FBW7 knockout mice were generated [75].
These mice have markedly lower levels of hemoglobin and plate-
lets at early age; however, these levels stopped decreasing around
12 weeks [75]. About 30% of FBW7-BM-deﬁcient mice exhibited
extremely severe pancytopenia in 12 weeks post-depletion of
FBW7. Speciﬁcally, the numbers of BMmononuclear cells including
all lineages of hematopoietic cells are signiﬁcantly decreased [75].
Moreover, p53 expression levels were increased in BM cells
derived from FBW7-deﬁcient mice at 4 weeks, while p53 protein
levels were down-regulated in BM mononuclear cells of FBW7-
deﬁcient mice at 12 weeks, suggesting that the fate of FBW7-deﬁ-
cient hematopoietic cells is determined by p53 expression [75].
Furthermore, more than half of FBW7-BM-deﬁcient mice devel-
oped T-ALL within 16 weeks. Lymphoid blasts invaded BM and
many organs including liver, spleen, thymus, and kidney in the leu-
kemic mice [75]. More importantly, leukemic cells of FBW7-deﬁ-
cient mice showed marked accumulation of Notch-1 and c-Myc
proteins, indicating that high expression of Notch-1 and c-Myc in
FBW7-deﬁcient BM cells may lead to the development of T-ALL
[75]. Additionally, deletion of p53 in FBW7-BM-deﬁcient mice
caused T-cell malignancies with a much shorter latency and died
within 12 weeks, demonstrating that p53 could suppress leukemo-
genesis in FBW7-BM deﬁcient mice [75]. In support of the critical
role of FBW7 in tumorigenesis, similar results in BM-speciﬁc
FBW7 knockout mice were obtained by the Alfantis group [80] as
well, echoing the frequently identiﬁcation of FBW7 mutation and
deletion in human T-ALL patients.
3.2.3. FBW7/ in the intestine
Recently, Sancho et al. generated conditional gut-speciﬁc
knockout mice lacking FBW7 speciﬁcally in the intestinal tissue
and investigated the function of FBW7 in intestine [79]. Mice with
FBW7 deletion in the gut were viable and fertile and did not exhibit
any gross phenotypic alteration. Moreover, these mice have a dras-
tic decrease of goblet and paneth cells, as well as an increased
enteroendocrine numbers [79], suggesting that FBW7 is a regulator
of intestinal cell fate decisions. Furthermore, accumulation of
progenitor cells was found in the absence of FBW7 in the gut. More
importantly, it showed a signiﬁcant increase in Notch-1 and c-Jun
in the conditional FBW7 deletion mice in the intestines [79].
Although FBW7-intestine-deﬁcient mice showed the accumulation
of actively proliferating progenitor cells, these mice did not
develop intestinal tumors. However, genetic loss of FBW7 in intes-
tine affects the APC (adenomatous polyposis coli-mediated
tumorigenesis)-mediated intestinal tumorigenesis. Speciﬁcally,
the complete absence of FBW7 caused an increase in both tumor
number and tumor size, thus leading to decreased survival rate
in APCmin/+ mice [79]. Moreover, both c-Jun and Notch-1 are signif-
icantly upregulated in APCmin/+; FBW7/mice. Deletion of c-Jun in
APCmin/+; FBW7/ mice reduced tumor size but not tumor num-ber, indicating that c-Jun might be an important factor to control
tumor size, instead of tumor initiation [79]. Taken together, these
results suggest that FBW7 functions as a haploinsufﬁcient tumor
suppressor of intestinal tumors induced by APC mutation that is
frequently observed in human intestinal tumors.
3.2.4. FBW7/ in the liver
Recently, Onoyama et al. generated mice with liver-speciﬁc null
mutations of FBW7 [77]. They found that the livers of these mice
were enlarged and lighter in color with massive lipid deposition
and non-alcoholic steatohepatitis-like lesions in the FBW7-deﬁ-
cient liver [77]. Consistent with this observation, they showed that
the accumulation of SREBP, which is one of many target of FBW7,
led to triglyceride deposition in the liver, which in turn affects
the expression of other adipogenic and lipogenic genes such as
ChREBP (carbohydrate response element-binding protein), PPARc
(peroxisome proliferator-activated receptor gamma) as well as
their downstream targets including Fas (fatty acid synthase),
SCD1 (stearoyl CoA desaturase-1), LDLR (LDL receptor) and
HMGCS1 (HMG-CoA synthase) through a negative feedback loop
[77]. Moreover, cell proliferation was increased in FBW7-deﬁcient
liver. As a result, FBW7-deﬁcient liver eventually led to marked
proliferation of the biliary system and development of hamartomas
[77]. More importantly, skewed hepatic differentiation in the
FBW7-deﬁcient liver is possibly due to Notch-1 accumulation
and upregulation of its target genes such as Hes-1 and Hey-1
[77]. Taken together, FBW7 plays a pivotal role in governing lipo-
genesis, cell proliferation and differentiation in the liver.
3.2.5. FBW7/ in the brain and breast
To examine the consequences of FBW7 deﬁciency in the brain,
the group led by Dr. Nakayama generated mice with conditional
ablation of FBW7 in the brain [74]. Mice with brain-speciﬁc dele-
tion of FBW7 died within 24 h after birth with smaller body and
absence of milk in the stomach, indicating that their death could
be due to a defect in suckling behavior [74]. Moreover, the mutant
mice have substantial changes in their brain structure. For exam-
ple, the third ventricle was dilated and distorted with horizontal
sulcus in their brains [74]. The cellularity of the cortex was also re-
duced in the brain of FBW7/mice. Furthermore, accumulation of
Notch-1 and Notch-3 was found in the FBW7-deﬁcient brain [74].
They further demonstrated that FBW7-dependent degradation of
Notch is required for normal brain development [74]. Another
group also independently showed similar results that mice with
conditional inactivation of FBW7 in the nervous system did not
survive to weaning age [73]. More importantly, Hoeck et al. used
this mouse model to show that FBW7 controls neural stem cell dif-
ferentiation and progenitor cell apoptosis by antagonizing the
Notch and c-Jun signaling [73]. Lastly, in line with a role of FBW7
in tumorigenesis, mammary epithelium-speciﬁc FBW7 knockout
mice quickly developed breast cancer [76].
3.2.6. FBW7/ in mouse embryonic ﬁbroblasts
To study the physiological role of FBW7 in a tissue culture mod-
el, Dr. Nakayama’s laboratory conditionally ablated FBW7 in MEFs
(mouse embryonic ﬁbroblasts) [81]. They reported that FBW7/
MEFs were ﬂattened and detached spontaneously from the culture
dish under conventional culture conditions [81]. Additionally, the
proliferation of FBW7/ MEFs was signiﬁcantly decreased. More-
over, ablation of FBW7 reduced cell growth via induction of cell cy-
cle arrest at G1 phase and increased frequency of apoptosis [81].
Surprisingly, inhibition of cell growth by loss of FBW7 in MEFs
was accompanied by increased abundance of Notch-1. Further-
more, both induction of cell cycle arrest and increased apoptosis
in FBW7/MEFs require Notch-RBP-J (recombination signal bind-
ing protein for immunoglobulin kappa J region) signaling pathway
1414 Z. Wang et al. / FEBS Letters 586 (2012) 1409–1418[81]. Interestingly, the cell cycle arrest by ablation of FBW7 in
MEFs was dependent on the p53 pathway, whereas increased
apoptosis in these MEFs was mediated via a p53-independent
pathway [81]. Recently, Dr. Nakayama’s group further demon-
strated that ablation of FBW7 led to aberrant activation of Notch-
1, which in turn inhibited the expression of p27 and p57 but pro-
moted the expression of p21 and p53 [82]. The p19 expression was
dependent on c-Myc, whereas accumulation of p16 was found to
be independent on Notch and c-Myc in FBW7/MEFs [82]. There-
fore, these unexpected results argued that FBW7may not only play
a tumor suppressor role in MEFs, it also suggests that FBW7 could
have different effects in different tissues in a context-dependent
manner.
3.3. FBW7+/ mice
Although homozygous FBW7/ embryos die, heterozygous
mice appeared normal and were fertile [11]. FBW7+/ mice have
no obvious phenotypes and do not develop spontaneous tumors
up to 12 months of age [11]. It is possible that FBW7+/ mice will
develop the tumors later in life. Therefore, loss of FBW7 could con-
tribute to cancer in mice under the proper conditions, such as com-
bination with overexpression of oncogenes or deletion of tumor
suppressor genes. For example, Dr. Mao et al. found that FBW7+/
mice have susceptibility to radiation-induced tumorigenesis, but
most tumors have the wild-type allele, suggesting that FBW7 has
the properties of a haploinsufﬁcient tumor suppressor gene [83].
In line with this concept, both FBW7/ and FBW7+/ cells from
embryonic day 9.5 embryos showed almost the same degree of
expression of increased Aurora-A and Notch-4 [83]. Additionally,
lung adenocarcinoma, hepatocarcinoma and haemangiosarcoma
were found in the irradiated FBW7+/ mice [83]. To further inves-
tigate the function of FBW7 in tumorigenesis, this group detected
the radiation-induced tumorigenesis in p53-deﬁcient, FBW7-deﬁ-
cient mice, and double deﬁcient mice. As expected, morn than
30% of irradiated mice developed tumors in FBW7+/ mice,
whereas no spontaneous tumors were found in unirradiated
FBW7+/mice [83]. Moreover, it showed accelerated tumorigenesis
in irradiated FBW7+//p53+/ mice compared with p53+/ mice.
Furthermore, the FBW7+//p53+/ mice developed a wide range of
tumors in epithelial tissues including lung, liver and ovary [83].
Thus, these results suggest that FBW7 is a haploinsufﬁcient tumor
suppressor gene.
Recently, Sancho et al. generated conditional knockout FBW7+/
mice lacking one allele of FBW7 in the intestine and investigated
the effect of FBW7 absence in APC-mediated tumorigenesis [79].
These FBW7+/ mice have no other phenotypic alteration and no
accumulation of progenitor cells. However, FBW7+/ heterozygous
mutation increased the number of tumors in APCmin/+ mice [79].
Interestingly, unlike FBW7 homozygous mutation, heterozygosity
for FBW7 did not increase tumor size [79]. More importantly, the
survival rate was decreased in APCmin/+ mice with an FBW7 hetero-
zygous situation. In addition, Notch-1 was remarkably increased in
FBW7+//APCmin/+ tumors [79], suggesting that Notch-1 could con-
tribute to colon cancer in these mice.4. FBW7 in human tumor tissues
In line with the genetic information obtained from the various
Fbw7 knockout mouse models, it has been well documented that
FBW7 serves as a tumor suppressor due to its negative regulation
of oncoproteins that are frequently overexpressed in human can-
cers [3]. Therefore, loss of FBW7 by means of mutation and/or dele-
tion is often observed in a variety of tumors including breast
cancer, colon cancer, T-ALL (T-cell acute lymphoblastic leukemia),prostate cancer, pancreatic cancer, and gastric cancer [3]. To eval-
uate the suppressive role of FBW7 in human tumorigenesis, Akho-
ondi et al. preformed a comprehensive genetic screen of primary
tumors [84]. This study led to the discovery that FBW7 is inacti-
vated by mutation in various types of human malignances with
an overall mutation frequency of approximately 6% [84]. Speciﬁ-
cally, the mutation frequencies identiﬁed in tumors of cholangio-
carcinomas, T-ALL, endometrium, colon, stomach are 35%, 31%,
9%, 9%, and 6%, respectively [84].
In separate studies from multiple other groups have conﬁrmed
the frequent FBW7 mutations in human cancers [61,85,86]. For
example, Spruck et al. found that FBW7 is mutated in at least
16% of human endometrial tumors [85]. Moreover, FBW7 muta-
tions were also identiﬁed in both human colorectal cancers and
their precursor lesions [61]. Consistent with this notion, Yakobori
et al. identiﬁed that lower expression of FBW7 contributed to
lymph node metastasis, tumor size, and poor prognosis in gastric
cancer [86]. Furthermore, this group found that patients diagnosed
with gastric cancer with low FBW7 expression and p53 mutation
had a distinct poor prognosis, suggesting that synergistic disrup-
tion of both p53 and FBW7 contributes to poor prognosis for cancer
patients [86]. Additionally, genetic alterations in the FBW7 locus
was found in 6% of human prostate cancer while differential
expression of FBW7 isoforms was inversely correlated with ad-
vanced stage and recurrence in prostate cancer [87]. Study from
another group also demonstrated that FBW7 mutations, which
lead to high expression of Cyclin E, play a critical role in the devel-
opment of human pancreatic cancer [88]. Recently, it has also been
shown that loss of FBW7 in the gut altered homeostasis of the
intestinal epithelium, leading to elevated Notch and c-Jun expres-
sion that subsequently induced the development of adenomas
[89]. In further support of the tumor suppressor role of FBW7 in
carcinogenesis, FBW7 mutations were observed in adult T-cell
and B-cell acute lymphocytic leukemias [90]. Taken together, these
results suggest that FBW7 functions as a tumor suppressor in the
genesis of various types of human cancers. Interestingly, mutations
of FBW7 were infrequent in ovarian cancer and breast cancer, sug-
gesting the existence of other ways for inactivation of FBW7 in
facilitating human malignances [91,92]. Indeed, Akhoondi et al.
identiﬁed that FBW7 promoter hypermethylation also contributes
to inactivation of FBW7 in human breast cancer, which is associ-
ated with poorly differentiated tumors [91]. However, further in-
depth investigation is required to deﬁne the exact molecular mech-
anism underlying the anti-tumor activity of FBW7 as well as the
mechanism by which the expression of FBW7 is regulated, and
how the loss of FBW7 contributes to the development of human
cancers.5. Conclusions
In conclusion, FBW7, a well-characterized tumor suppressor, is
frequently mutated or depleted in a variety of human malignances.
FBW7 exerts its tumor suppressor function through regulation of
many key substrates including Mcl-1, Notch, c-Jun, c-Myc, Cyclin
E, HIF1a, mTOR, and KLF5, most of which possess strong oncogenic
roles (Fig. 2). Furthermore, the observations from the multiple
FBW7 knockout mouse models as shown in Fig. 3 suggested that
accumulation of FBW7 substrates in response to ablation of
FBW7 occurs in a tissue-speciﬁc manner, leading to the differences
in the phenotypic consequence of FBW7 deletion [76]. More
importantly, FBW7 speciﬁcally recognizes phosphorylated sub-
strates, which is dependent on the balance of various kinase activ-
ities in a cell type- or developmental stage-speciﬁc manner [81]. In
addition, the ﬁndings from FBW7+//p53+/ mice and FBW7+//
APCmin/+ mice indicated that the FBW7 heterozygote may have
Fig. 2. Illustrated signaling pathways for FBW7-mediated degradation of its major downstream targets as well as the identiﬁed FBW7 upstream regulators. The speciﬁc
substrates of FBW7 include Mcl-1, c-Jun, c-Myc, Cyclin E, HIF1a, Notch, c-Myb, KLF5, mTOR, and SREBP. Several proteins such as p53 and C/EBP-d, and microRNAs including
miR-27a and miR-223 are found to regulate the expression of FBW7. C/EBP-d: CCAAT/enhancer-binding protein-d; HIF1a: Hypoxia inducible factor 1a; KLF5: Krüppel-like
factor 5; Mcl-1: Myeloid cell leukemia-1; mTOR: mammalian target of rapamycin; NF1: Neuroﬁbromatosis type 1; NRF1: Nuclear factor E2-related factor 1; SREBP: Sterol
regulatory element-binding proteins.
Fig. 3. Illustrated presentation of the various FBW7 knockout mouse models including FBW7/, conditional FBW7/ and FBW7+/mouse models, which coherently support
the tumor suppressor role of Fbw7 in vivo.
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second hit [93,94].
Since most studies focus on identifying the targets of FBW7
ubiquitin ligase pathway, relatively little is known currently about
the regulation of FBW7 expression itself that lead to inactivation of
FBW7 in human malignances. Recently, accumulated evidence has
shown that several molecules such as p53 and C/EBP-d (CCAAT/en-
hancer-binding protein-d), as well as miRNAs (microRNAs) includ-
ing miR-27a and miR-223 can regulate FBW7’s tumor suppressor
functions [83,95–99] (Fig. 2). In this regard, a better understandingof the upstream regulator for FBW7 could provide important in-
sights for scientists and physicians to design better strategies to re-
store the FBW7 tumor suppressor function as an efﬁcient means to
treat cancer patients. Furthermore, FBW7 was recently found to be
involved in drug resistance [12,13], suggesting that targeting FBW7
may open a newer therapeutic window for drug administration.
However, a critical concern is how to design and ﬁnd speciﬁc com-
pounds to restore only FBW7 activity, but not affecting other sig-
naling pathways without causing unwanted side effects.
Recently, natural compound oridonin has been reported to activate
1416 Z. Wang et al. / FEBS Letters 586 (2012) 1409–1418FBW7 E3 ubiquitin ligase, leading to inhibition of c-Myc pathway
[100]. Obviously, the more knowledge we gain in terms of the up-
stream regulator and downstream targets of FBW7, the better we
can achieve more targeted activation of the FBW7 signaling
pathway to suppress tumorigenesis. In addition, it will be useful
to proﬁle the FBW7 status of individual tumor, such as mRNA
and protein levels, in guiding the optimization of personalized
medicines to achieve better clinical treatment. We anticipate that
directly or indirectly targeting FBW7 could offer novel strategies
to beneﬁt better treatment of cancer patients in the near future.
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